Zalifrelimab

Zalifrelimab (AGEN1884) is a fully human IgG1 monoclonal antibody targeting CTLA-4 (CTLA-4) . Zalifrelimab antagonizes the inhibitory checkpoints of immune cell activation regulated by CTLA-4 signaling[1].

Product Specifications

CAS Number

[2148321-69-9]

Product Name Alternative

AGEN1884

UNSPSC

12352203

Target

CTLA-4

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/zalifrelimab.html

Purity

98.28

Solubility

10 mM in DMSO

Smiles

[Zalifrelimab]

Molecular Weight

(144.48 kDa)

References & Citations

[1]David M O'Malley, et al. Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study. J Clin Oncol. 2022 Mar 1;40 (7) :762-771. |[2]Randi B Gombos, et al. Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody. PLoS One. 2018 Apr 4;13 (4) :e0191926.